Project Grant HT94252410793
Award Date
8/1/24
Completion Date
7/31/27
Dollars Obligated
$1.2M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Doylestown, PA 18901, USA
Similar Awards
The Department of Defense (DoD) has awarded a $846,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Institute For Cancer Research, a non-profit research organization, to investigate PALB2 mutant breast cancer. The funding supports a 3-year research project from August 1, 2024 to July 31, 2027. As the prime grantee, The Institute For Cancer Research will conduct innovative scientific studies and clinical trials focused on developing new treatments...
This $160,000 Project Grant awarded by the Defense Health Agency (DHA) under the Department of Defense's Military Medical Research and Development program (CFDA 12.420) is supporting research by the Baruch S. Blumberg Institute to enhance natural killer cell cytotoxicity toward cholangiocarcinoma. The goal of this one-year project is to explore mechanisms to improve the ability of natural killer cells to target and kill cholangiocarcinoma, a type of liver cancer. The Baruch S. Blumberg...
The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $1,128,000 Project Grant to The Institute For Cancer Research to conduct research on "Restoring PALB2 Function as a Mechanism of PARP1 Resistance in BRCA1-Mutant EOC". The award, with a performance period from July 1, 2024 to June 30, 2028, supports innovative scientific research aimed at improving health outcomes for military service members, veterans, and the broader...
This $838,911 Project Grant awarded by the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports research by The Institute For Cancer Research to identify regulators of PALB2 function and PARP inhibitor resistance in triple-negative breast cancer. The 3-year award, beginning January 2024, will fund work to advance the understanding of genetic and molecular mechanisms underlying treatment resistance in this aggressive form of breast cancer. As a prime...
The Baylor College of Medicine will use a $1.6 million Project Grant from the Defense Health Agency to research germline variants and population-wide breast cancer risk. The grant was awarded on February 1, 2023 under the Military Medical Research and Development program (CFDA 12.420). Through basic, applied, and advanced biomedical research, this project aims to transform healthcare for service members and the public by investigating medical solutions for the battlefield and developing...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
The Department of Defense's Defense Health Agency awarded a $1,821,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Wistar Institute of Anatomy and Biology, an independent biomedical research institute in Philadelphia. The grant, awarded on May 15, 2024, supports research into the "Immunomodulatory Role of Acetate Metabolism in Breast Cancer" over a 3-year performance period ending on May 14, 2027. As a recognized leader in cancer,...
The U.S. Department of Defense's Defense Health Agency awarded a $752,000 Project Grant to The Institute For Cancer Research, a subsidiary of Temple University, to investigate therapeutic response disparities in locally advanced rectal cancer. This grant, funded under the Military Medical Research and Development program (CFDA 12.420), supports basic, applied, and advanced biomedical research to transform health care for service members and the public through innovative and impactful research....
The Department of Defense's Defense Health Agency awarded a $447,612 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Beckman Research Institute of the City of Hope. The grant supports the development of a "highly tumor-specific oncolytic virus in combination with a viral protein-target T cell engager for the treatment of triple-negative breast cancer." The award period runs from January 1, 2024 to December 31, 2026. As a nonprofit...
This federal Project Grant award of $654,090.00 from the Defense Health Agency is for the "CANCER CELL INTRINSIC REGULATION OF ANTIBODY-DRUG CONJUGATE TARGETS IN BLADDER CANCER" research project at Pennsylvania State University's Milton S. Hershey Medical Center. The research, which runs from September 30, 2024 to September 29, 2026, is funded under the Military Medical Research and Development (CFDA 12.420) program. The project aims to investigate innovative approaches to cancer...